RADX
Radiopharm·NASDAQ
--
--(--)
--
--(--)
0.95 / 10
Underperform
Comprehensive fundamental analysis reveals significant weaknesses: Total operating revenue and Operating revenue YoY growth rates are high but historically associated with negative returns; Days sales outstanding is elevated at 564.1363, placing it in Group 3 with a quality score of 0/3. Only the Interest coverage ratio (42.4848) shows a positive score of 2/3, indicating limited ability to cover interest expenses. The overall fundamental score is 0.9/10, confirming weak fundamentals and a defensive stance.
Analysis Checks(1/4)
Total operating revenue (YoY growth rate %)
Value1114.27
Score1/3
Weight10.66%
1M Return-0.79%
Value1114.27
Score1/3
Weight10.66%
1M Return-0.79%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight14.56%
1M Return-1.11%
Value42.48
Score2/3
Weight14.56%
1M Return-1.11%
Days sales outstanding
Value564.14
Score0/3
Weight64.51%
1M Return-5.18%
Value564.14
Score0/3
Weight64.51%
1M Return-5.18%
Operating revenue (YoY growth rate %)
Value1114.27
Score1/3
Weight10.27%
1M Return-0.76%
Value1114.27
Score1/3
Weight10.27%
1M Return-0.76%
Total operating revenue (YoY growth rate %)
Value1114.27
Score1/3
Weight10.66%
1M Return-0.79%
Value1114.27
Score1/3
Weight10.66%
1M Return-0.79%
Days sales outstanding
Value564.14
Score0/3
Weight64.51%
1M Return-5.18%
Value564.14
Score0/3
Weight64.51%
1M Return-5.18%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight14.56%
1M Return-1.11%
Value42.48
Score2/3
Weight14.56%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value1114.27
Score1/3
Weight10.27%
1M Return-0.76%
Value1114.27
Score1/3
Weight10.27%
1M Return-0.76%
Is RADX fundamentally strong?
- RADX scores 0.95/10 on fundamentals and holds a Premium valuation at present. Backed by its -104.53% ROE, -1055.27% net margin, -2.43 P/E ratio, 2.08 P/B ratio, and 86.04% earnings growth, these metrics solidify its Underperform investment rating.
